Sign in

GMED on NYSE

Globus Medical

Logo: globusmedical.com5

American medical device company

Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.3 Its shares trade on NYSE under the symbol GMED.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

2003Founded1

Compare with West Pharmaceutical Services (United States), MiniMed Group, Inc. or Insulet (United States), or pick any stock.

  • TickerGMED on NYSE1
  • Industrymedical technology1
  • HeadquartersAudubon1
  • Websitewww.globusmedical.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address2560 General Armistead Avenue, Audubon, Pa 194036
  • Filer categoryLarge accelerated filer6
  • LEI5299003M2P4CIK0RF2054
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered address251 LITTLE FALLS DRIVE, c/o CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 36313074

See how the biggest companies compare on our leaderboards

Globus Medical image from its website
Image: globusmedical.com9

Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

16.3%Operating margin10
18.3%Net margin10
16.7%Revenue growth, 202510
11.8%Return on equity10
$588.8MFree cash flow10

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Musculoskeletal Solutions brought in 95% of the revenue Globus Medical broke down this way in fiscal 2025.

  1. Musculoskeletal Solutions$2.8B1095%up 18% from 2024
  2. Enabling Technologies$141.0M105%down 8% from 2024
Products and services by year
Products and services202320242025
Musculoskeletal Solutions$1.4B$2.4B$2.8B
Enabling Technologies$120.2M$154.0M$141.0M

Regions

United States brought in 81% of the revenue Globus Medical broke down this way in fiscal 2025.

  1. United States$2.4B1081%up 18% from 2024
  2. Outside the United States$571.3M1019%up 10% from 2024
Regions by year
Regions202320242025
United States$1.3B$2.0B$2.4B
Outside the United States$288.7M$519.3M$571.3M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue33¢$957.8M
  • Research and development5¢$147.2M
  • Selling, general and admin40¢$1.2B
  • Other costs2¢$50.3M
  • Income tax2¢$67.2M
  • Profit18¢$537.9M

Out of $2.9B in revenue.10

Where each dollar of operating cash went, fiscal 2025

  • Capital spending22¢$164.7M
  • Share buybacks40¢$300.5M
  • Kept or used elsewhere38¢$288.3M

Out of $753.4M of cash from operations.10

Financial statements

Revenue1112131410$2.9B in 2025+274% since 2019
0$1.0B$2.0B$3.0B2019: $785.4M$785.4M20192020: $789.0M$789.0M2020+0%2021: $958.1M$958.1M2021+21%2022: $1.0B$1.0B2022+7%2023: $1.6B$1.6B2023+53%2024: $2.5B$2.5B2024+61%2025: $2.9B$2.9B2025+17%
Gross profit111213$1.0B in 2023+69% since 2019
0$500.0M$1.0B$1.5B2019: $605.4M$605.4M20192020: $571.6M$571.6M2020−6%2021: $718.9M$718.9M2021+26%2022: $759.1M$759.1M2022+6%2023: $1.0B$1.0B2023+34%
Operating income1112131410$479.8M in 2025+179% since 2019
0$200.0M$400.0M$600.0M2019: $172.0M$172.0M20192020: $111.4M$111.4M2020−35%2021: $172.0M$172.0M2021+54%2022: $228.0M$228.0M2022+33%2023: $133.1M$133.1M2023−42%2024: $166.0M$166.0M2024+25%2025: $479.8M$479.8M2025+189%
Net income1112131410$537.9M in 2025+247% since 2019
0$200.0M$400.0M$600.0M2019: $155.2M$155.2M20192020: $102.3M$102.3M2020−34%2021: $149.2M$149.2M2021+46%2022: $190.2M$190.2M2022+27%2023: $122.9M$122.9M2023−35%2024: $103.0M$103.0M2024−16%2025: $537.9M$537.9M2025+422%

Every line of the income statement as filed: the last 3 fiscal years, latest first.10

Period ending2025-12-312024-12-312023-12-31
Net sales$2.9B$2.5B$1.6B
Cost of sales (exclusive of amortization of intangibles)$957.8M$1.0B$548.2M
Research and development$147.2M$163.8M$124.0M
Selling, general and administrative$1.2B$981.4M$643.8M
Amortization of intangibles$118.2M$119.4M$51.0M
Acquisition-related costs$42.3M$29.6M$68.3M
Restructuring costs$15.0M$23.8M$0
Operating income/(loss)$479.8M$166.0M$133.1M
Interest income/(expense), net$7.1M-$4.2M$20.1M
Foreign currency transaction gain/(loss)-$3.0M-$43.3M$14.3M
Bargain purchase gain$117.7M$0$0
Other income/(expense)$3.4M$2.2M-$2.1M
Total other income/(expense), net$125.3M-$45.3M$32.3M
Income/(loss) before income taxes$605.1M$120.7M$165.4M
Income tax provision/(benefit)$67.2M$17.7M$42.5M
Net income/(loss)$537.9M$103.0M$122.9M
Unrealized gain/(loss) on marketable securities$448.0K$1.5M$13.2M
Foreign currency translation gain/(loss)$21.8M$1.8M$1.2M
Total other comprehensive income/(loss), net of tax$22.2M$3.3M$14.4M
Comprehensive income/(loss)$560.1M$106.3M$137.3M
Basic (in USD per share)$3.98$0.76$1.09
Diluted (in USD per share)$3.92$0.75$1.07
Basic (in shares)135.2M shares135.7M shares113.1M shares
Diluted (in shares)137.1M shares137.9M shares114.6M shares

Compare Globus Medical with another company

Corporate structure

Globus Medical sits at the top of its group. 22 entities, 11 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Globus Medical

  • Globus Medical Audubon, Pennsylvania, United States
    • Branch Medical Group, LLC Subsidiary · Delaware, United States
    • Fibriant BV Subsidiary · Netherlands
    • Globus Medical Brazil LDTA Subsidiary · Brazil
    • GLOBUS MEDICAL INDIA PRIVATE LIMITED Subsidiary · Chennai, India
    • Globus Medical Ireland LTD Subsidiary · Ireland
    • Globus Medical Japan GK Subsidiary · Japan
    • Globus Medical North America LLC Subsidiary · Pennsylvania, United States
    • Globus Medical Technology International, LLC Subsidiary · Delaware, United States
    • KB Medical SA Subsidiary · Switzerland
    • Nemaris, Inc. Subsidiary · Delaware, United States
    • Nevro Medical SRL Subsidiary · Costa Rica
    • Nevro, LLC Subsidiary · Delaware, United States
    • NuVasive (AUST/NZ) Pty. Ltd. Subsidiary · Australia
    • NuVasive Clinical Services Monitoring Inc. Subsidiary · Delaware, United States
    • NuVasive Germany GmbH Subsidiary · Germany
    • NuVasive Italia S.r.l. Subsidiary · Italy
    • NuVasive Japan K.K. Subsidiary · Japan
    • NUVASIVE NETHERLANDS B.V. Subsidiary · Amstelveen, Netherlands
    • NuVasive, LLC Subsidiary · Delaware, United States
    • Simplify Medical Pty. Ltd. Subsidiary · Australia
    • Transplant Technologies of Texas LTD Subsidiary · Texas, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Globus Medical reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.3B10 Dec 31, 2025$1.1B10 Dec 31, 2024+14.6%
Accumulated depreciation$705.0M10 Dec 31, 2025$545.8M10 Dec 31, 2024+29.2%
Property and equipment, net$564.5M10 Dec 31, 2025$561.9M10 Dec 31, 2024+0.5%
Finance-lease assets$718.0K10 Dec 31, 2025$518.0K10 Dec 31, 2024+38.6%
Operating-lease assets (leased space)$63.8M10 Dec 31, 2025$49.6M10 Dec 31, 2024+28.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$526.2M10 Dec 31, 2025$784.4M10 Dec 31, 2024−32.9%
Marketable securities, current$31.1M10 Dec 31, 2025$105.6M10 Dec 31, 2024−70.6%
Marketable securities, non-current$71.8M10 Dec 31, 2025$66.1M10 Dec 31, 2024+8.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.4B10 Dec 31, 2025$1.4B10 Dec 31, 2024+0.2%
Intangible assets, net (excluding goodwill)$745.1M10 Dec 31, 2025$795.1M10 Dec 31, 2024−6.3%
Finite-lived intangibles, gross$1.1B10 Dec 31, 2025$1.0B10 Dec 31, 2024+6.8%
Accumulated amortization$372.1M10 Dec 31, 2025$251.1M10 Dec 31, 2024+48.2%
Finite-lived intangibles, net$745.1M10 Dec 31, 2025$795.1M10 Dec 31, 2024−6.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$759.3M10 Dec 31, 2025$659.2M10 Dec 31, 2024+15.2%
Raw materials$162.2M10 Dec 31, 2025$122.0M10 Dec 31, 2024+33.0%
Work in process$64.5M10 Dec 31, 2025$45.8M10 Dec 31, 2024+40.8%
Finished goods$532.6M10 Dec 31, 2025$491.5M10 Dec 31, 2024+8.4%

Properties, in its own words

Our owned corporate headquarters are located in Audubon, Pennsylvania. We have additional leased domestic administrative offices, research and training facilities in Arizona, California, Colorado, Illinois, Maryland, New Jersey, North Carolina and Texas (one facility in Texas is owned). Our owned manufacturing and fulfillment facilities are located in Massachusetts, Ohio, Pennsylvania and Tennessee. We maintain leased distribution warehouses and administrative offices in fourteen additional countries.

Item 2 of the 10-K filed Feb 24, 2026.19

Leadership

Who has led Globus Medical, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David C. Paul2012–2017
  2. David M. Demski2017–2022
  3. Daniel T. Scavilla2022–2025
  4. Keith W. Pfeil2025–now

Chair

  1. David C. Paul2018–now

President

  1. David M. Demski2012–2022
  2. A. Brett Murphy2015–2017
  3. Daniel T. Scavilla2022–2025
  4. Keith W. Pfeil2025–now

Chief financial officer

  1. Richard A. Baron2012–2014
  2. Daniel T. Scavilla2015–2019
  3. Keith W. Pfeil2019–2025
  4. Kyle Kline2025–now

Chief operating officer

  1. David M. Demski2012–2015
  2. Keith W. Pfeil2025–now
20052010201520202025
Board members and other officers (20)

Products and brands

  • medical device

Listed on Wikidata.1

Globus develops, manufactures, and markets orthopedic implants including spine, trauma, and artificial joints.

Globus Medical makes the ExcelsiusGPS surgical robotic system for spine surgery. The robot is used for transpedicular drilling and screw placement. In November 2024, the company launched its ExcesiusHub, an advanced surgical navigation system for robotic surgical procedures.

The ADIRA XLIF Plate System aids in enhancing lateral spine surgery procedures.

From Wikipedia’s article on Globus Medical, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Branch Medical Group, LLC Delaware8
  • Fibriant BV Netherlands8
  • Globus Medical B.V. Netherlands8
  • Globus Medical Brazil LDTA Brazil8
  • Globus Medical Ireland LTD Ireland8
  • Globus Medical Japan GK Japan8
  • Globus Medical North America LLC Pennsylvania8
  • Globus Medical Technology International, LLC Delaware8
  • KB Medical SA Switzerland8
  • Nemaris, Inc. Delaware8
  • Nevro Medical SRL Costa Rica8
  • Nevro, LLC Delaware8
  • NuVasive (AUST/NZ) Pty. Ltd. Australia8
  • NuVasive Clinical Services Monitoring Inc. Delaware8
  • NuVasive Germany GmbH Germany8
  • NuVasive Italia S.r.l. Italy8
  • NuVasive Japan K.K. Japan8
  • NuVasive Netherlands B.V. Netherlands8
  • NuVasive, LLC Delaware8
  • Simplify Medical Pty. Ltd. Australia8
  • Transplant Technologies of Texas LTD Texas8

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

In January 2014, Globus Medical acquired Excelsius Surgical. The Excelsius system is designed to integrate intra-operative digital imaging with a robotic surgery device to hold patients in place during surgeries "with sub-millimeter accuracy". In October of that year, the company acquired allograft tissue processor Transplant Technologies of Texas, Ltd. (TTOT). TTOT provides human tissue products, including bone allografts, biomaterials, and soft tissue products for spine, orthopedics, sports medicine, dental, and wound care markets.

In February 2015, Globus Medical acquired Branch Medical Group, a third-party manufacturer of high-precision medical devices.

In July 2016, Globus Medical acquired Alphatec Holdings, an international operations and distribution channel, for $80 million. As part of the transaction, Globus has agreed to provide Alphatec a five-year senior secured credit facility of up to $30 million.

In September 2018, Globus Medical acquired Nemaris, developers of Surgimap, a pre-operative planning software for spinal surgeons.

Read the full text

In August 2019, Globus Medical acquired privately owned StelKast, manufacturer of implants and instruments for hip and knee replacement.

In February 2023, Globus Medical acquired NuVasive in an all-stock deal valued at $3.1 billion.

From Wikipedia’s article on Globus Medical, shared under CC BY-SA 4.0.7

Timeline

  1. Aug 6, 20268-K Results of operations47
  2. Jun 4, 20268-K Executive or director change; Shareholder vote48
  3. May 7, 20268-K Results of operations49
  4. Mar 23, 20268-K Executive or director change; Regulation FD disclosure50
  5. Feb 24, 20268-K Results of operations51
  6. Jan 7, 20268-K Results of operations52
  7. Nov 6, 20258-K Results of operations53
  8. Aug 27, 2025New chief executive Keith W. Pfeil becomes CEO20
  9. Aug 7, 20258-K Results of operations54
  10. Jul 21, 20258-K Results of operations; Executive or director change; Regulation FD disclosure55
  11. Jun 5, 20258-K Executive or director change; Shareholder vote56
  12. May 15, 20258-K Other events57
  13. May 8, 20258-K Results of operations58
  14. Apr 22, 2022New chief executive Daniel T. Scavilla becomes CEO21
  15. Aug 30, 2017New chief executive David M. Demski becomes CEO22
  16. Aug 2, 2012New chief executive David C. Paul becomes CEO23
  17. 2003Founded Founded1

Calendar

Coming up

  1. Nov 5, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $1.18 a share, on Nov 6, 2025.59

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results47
  2. May 7, 2026Reported quarterly or annual results49
  3. Feb 24, 2026Reported quarterly or annual results51
  4. Jan 7, 2026Reported quarterly or annual results52
  5. Nov 6, 2025Reported quarterly or annual results53
  6. Aug 7, 2025Reported quarterly or annual results54
  7. Jul 21, 2025Reported quarterly or annual results55
  8. May 8, 2025Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

292 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 46 major events, 127 insider forms, 24 large holders, 74 other. The latest 20:

  1. Sep 16, 20264 EDGAR
  2. Sep 15, 2026144 EDGAR
  3. Aug 19, 20264 EDGAR
  4. Aug 18, 2026144 EDGAR
  5. Aug 6, 202610-Q EDGAR
  6. Aug 6, 20268-K EDGAR
  7. Jul 28, 20264 EDGAR
  8. Jun 9, 20264 EDGAR
  9. Jun 8, 20264 EDGAR
  10. Jun 5, 2026144 EDGAR
  11. Jun 4, 20268-K EDGAR
  12. May 27, 2026SD EDGAR
  13. May 7, 202610-Q EDGAR
  14. May 7, 20268-K EDGAR
  15. Apr 30, 2026SCHEDULE 13G EDGAR
  16. Apr 24, 2026DEFA14A EDGAR
  17. Apr 24, 2026DEF 14A EDGAR
  18. Apr 14, 2026144 EDGAR
  19. Mar 26, 2026SCHEDULE 13G/A EDGAR
  20. Mar 23, 20268-K EDGAR

The 292 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

42 open-market trades by officers, directors and large owners since October 2021: 0 buys and 42 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 15, 2026TOBIN JAMES RDirectorSale30,000$74.58$2.2MForm 4
Aug 18, 2026ZARRILLI STEPHEN TDirectorSale25,000$87.04$2.2MForm 4
Jun 5, 2026Davidar David DDirectorSale25,000$80.76$2.0MForm 4
Feb 25, 2026Huller KellyEVP, GC, Corporate SecretarySale20,000$94.50$1.9MForm 4
Feb 12, 2026Huller KellyEVP, GC, Corporate SecretarySale10,000$87.67$876.7KForm 4
Jan 8, 2026Kline KyleSenior Vice President, CFOSale3,594$101.10$363.4KForm 4
Jan 8, 2026Norwalk Leslie VDirectorSale2,000$101.10$202.2KForm 4
Dec 12, 2025Norwalk Leslie VDirectorSale4,000$88.85$355.4KForm 4
Dec 1, 2025Kline KyleSenior Vice President, CFOSale18,542$90.00$1.7MForm 4
Nov 25, 2025Huller KellyEVP, GC, Corporate SecretarySale7,500$90.00$675.0KForm 4
Nov 12, 2025Davidar David DDirectorSale25,000$86.00$2.1MForm 4
Nov 11, 2025ZARRILLI STEPHEN TDirectorSale25,000$84.29$2.1MForm 4
Nov 10, 2025RHOADS ANN DDirectorSale2,000$85.00$170.0KForm 4
Nov 7, 2025RHOADS ANN DDirectorSale8,000$81.00$648.0KForm 4
Sep 15, 2025RHOADS ANN DDirectorSale10,000$58.46$584.6KForm 4
Feb 28, 2025RHOADS ANN DDirectorSale7,500$78.68$590.1KForm 4
Jan 10, 2025Pfeil Keith WPresident, CEOSale14,167$88.29$1.3MForm 4
Dec 2, 2024Huller KellyEVP, GC, Corporate SecretarySale2,500$87.00$217.5KForm 4
Nov 22, 2024Davidar David DDirectorSale13,512$85.00$1.1MForm 4
Nov 22, 2024Lemaitre DanDirectorSale1,097$85.02$93.3KForm 4

All 42 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Daniel T. ScavillaFormer Chief Executive Officer and President$284.6K$5.3M67
2025Keith W. PfeilChief Executive Officer and President47$479.5K$4.4M67
2025David C. PaulChairman of the Board of Directors and Executive Chairman59$469.4K$4.3M67
2025Kelly G. HullerExecutive Vice President, General Counsel and Corporate Secretary54$364.1K$2.3M67
2025Kyle R KlineSenior Vice President and Chief Financial Officer41$334.0K$1.4M67
2024Daniel T. ScavillaFormer Chief Executive Officer and President$481.1K$4.9M67
2024David C. PaulChairman of the Board of Directors and Executive Chairman59$457.4K$3.1M67
2024Keith W. PfeilChief Executive Officer and President47$463.6K$2.4M67
2024Kelly G. HullerExecutive Vice President, General Counsel and Corporate Secretary54$357.3K$1.6M67
2023Daniel T. ScavillaFormer Chief Executive Officer and President$463.5K$4.6M67
2023David C. PaulChairman of the Board of Directors and Executive Chairman59$448.5K$3.2M67
2023Keith W. PfeilChief Executive Officer and President47$414.7K$2.1M67
2023Kelly G. HullerExecutive Vice President, General Counsel and Corporate Secretary54$344.2K$1.6M67

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.10,806,724$853.8M0.0%+309,310
Jupiter Topco LLC8,200,423$647.9M0.3%New
Vanguard Capital Management LLC5,107,532$403.5M0.0%+74,800
Vanguard Portfolio Management LLC4,994,385$394.6M0.0%+114,926
Invesco Ltd.4,309,771$340.5M0.0%−6,883
Kayne Anderson Rudnick Investment Management LLC4,279,730$338.1M1.1%New
State Street Corp3,714,029$293.5M0.0%+123,657
Sculptor Capital LP3,000,000$237.0M3.4%−58,000
Jpmorgan Chase & Co2,743,850$230.8M0.0%+148,542
Alliancebernstein L.P.2,380,344$205.1M0.1%+629,512
Bank Of Montreal /can/2,425,491$191.6M0.1%+118,310
Dimensional Fund Advisors LP2,369,310$187.3M0.0%+599,413
Geode Capital Management, LLC2,153,014$170.2M0.0%+40,890
Goldman Sachs Group Inc1,781,608$140.8M0.0%+649,446
Arrowstreet Capital, Limited Partnership1,716,621$135.6M0.1%+803,716
Boston Trust Walden Corp1,573,361$124.3M0.9%+318,451
Boston Partners1,554,990$122.8M0.1%New
Allspring Global Investments Holdings, LLC1,571,681$119.4M0.2%+1,143,641
Geneva Capital Management LLC1,417,067$112.0M2.6%−343,904
William Blair Investment Management, LLC1,284,896$101.5M0.3%−724,867
Charles Schwab Investment Management Inc1,246,322$98.5M0.0%+2,707
Quantinno Capital Management LP1,219,098$96.3M0.1%+672,003
Norges Bank1,127,051$89.0M0.0%New
Fuller & Thaler Asset Management, Inc.1,114,484$88.1M0.2%+12,916
Morgan Stanley1,094,753$86.5M0.0%+34,253

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

10 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Sep 3, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+1.1%Report
Aug 19, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$15,001 - $50,000−11.1%Report
Mar 3, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−27.5%Report
Jul 10, 2025Lisa C. McClainRepublican, HouseSale$1,001 - $15,000−13.1%Report
Jun 24, 2025Lisa C. McClainRepublican, HousePartial sale$1,001 - $15,000−7.2%Report
Jun 17, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000+6.4%Report
Apr 9, 2025Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+34.5%Report
Mar 6, 2023Daniel S. GoldmanDemocratic, HouseSale$15,001 - $50,000+57.6%Report
Feb 8, 2023Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+85.5%Report
Jan 11, 2023Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+88.0%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Globus Medical is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGLOBUS MEDICAL INC2
  • CIK0001237831
  • Employer ID (EIN)04-374495419
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company19
  • Incorporated inDelaware19
  • Fiscal year endsDecember 312
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address2560 General Armistead Avenue, Audubon, PA 194032
  • Phone610-930-18002
  • Shares outstanding134,261,914 as of Aug 4, 202616
  • Public float$6.6B as of Jun 30, 202519
  • AuditorDELOITTE & TOUCHE LLP, Philadelphia, Pennsylvania PCAOB ID 34; it also attests to the company’s internal control over financial reporting19
  • On EDGAR sinceMay 30, 20032
  • Filings772 in all: 4 (334), 8-K (129), SC 13G/A (53), 10-Q (43), 144 (40), 3 (25), DEFA14A (15), 10-K (14)2
    All 37 form types

    DEF 14A (14), SD (13), CORRESP (12), SC 13G (10), UPLOAD (9), 425 (7), REGDEX/A (7), 4/A (5), REGDEX (5), S-1/A (5), SCHEDULE 13G/A (5), S-8 (4), 10-K/A (3), 5 (2), EFFECT (2), FWP (2), NT 10-K (2), 10-Q/A (1), 3/A (1), 424B3 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), ARS (1), CERTNYS (1), S-1 (1), S-4 (1), S-4/A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Feb 24, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 24, 2026
    Latest 8-K (8-K) Aug 6, 2026

Securities registered for trading

ClassSymbolExchange
Class A Common Stock, par value $.001 per shareGMEDNew York Stock Exchange

From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).19

Risk factors and legal proceedings

The risks Globus Medical names in Item 1A of its 10-K filed Feb 24, 2026: 57 risks under these headings, as written.19

  • We are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the full risk factors contained in this Form 10-K in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from recent results or from our anticipated future results.
  • Risks Related to Our Business and Our Industry
  • Risks Related to our Legal and Regulatory Environment
  • Risks Related to our International Operations
  • Risks Related to our Financial Results and Need for Financing
  • Risks Related to our Intellectual Property and Potential Litigation
  • Risks Related to the Ownership of our Class A Common Stock
  • General Risk Factors
  • Risks Relating to Our Acquisitions
  • To be commercially successful, we must convince surgeons and hospitals that our products are an attractive alternative to our competitors’ products and that our Enabling Technologies and Musculoskeletal Solutions products are an attractive alternative to existing surgical treatments of musculoskeletal disorders.
  • Pricing pressure from our competitors and our customers may impact our ability to sell our products at prices necessary to support our current business strategies.
  • If our hospital and other healthcare provider customers are unable to obtain adequate coverage and reimbursement for their purchases of our Musculoskeletal Solutions products, we may not be able to sell our Musculoskeletal Solutions products at prices necessary to maintain our profitability or at all.
The other 53 risks
  • If we are unable to maintain and expand our network of direct sales representatives and independent distributors, we may not be able to generate anticipated sales.
  • We operate in a very competitive business environment and if we are unable to compete successfully against our existing or potential competitors, our sales, operating results, and growth may be negatively affected.
  • We are dependent on a limited number of third-party suppliers, and the loss of any of these suppliers, or their inability to provide us with an adequate supply of products or materials in a timely manner, could harm our business.
  • The proliferation of PODs could result in increased pricing pressure on our products or harm our ability to sell our products to physicians who own or are affiliated with those distributorships.
  • Our business could suffer if we lose the services of key members of our senior management, key advisors or personnel, and if we do not successfully manage the transition associated with the resignation of our former chief executive officer and the appointment of our new chief executive officer, it could have an adverse impact on our business.
  • The safety and efficacy of our products is not yet supported by long-term clinical data, which could limit sales, and our products might therefore prove to be less safe and effective than initially thought.
  • If we do not enhance our existing product offerings and introduce new products through our research and development and product development efforts, we may be unable to effectively compete.
  • We are required to maintain high levels of inventory, which could consume a significant amount of our resources and reduce our cash flows.
  • We rely on information technology systems and network infrastructure to operate and manage our business, if we experience a breach, cyber-attack or other disruption to these systems or data, our business, results of operations and financial condition could be adversely affected.
  • We are subject to data privacy laws and our failure to comply with them could subject us to substantial liabilities.
  • If we experience significant disruptions in our information technology systems, our business, results of operations and financial condition could be adversely affected.
  • The increasing utilization of AI in the medical device and healthcare industries presents novel obstacles and risks to our business.
  • Consolidation in the healthcare industry could lead to demands for price concessions or to the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, results of operations or financial condition.
  • If our Enabling Technologies products require significant amounts of service after sale or we receive a significant number of warranty claims, our costs may increase, and our financial results may be adversely affected.
  • We experience long and variable capital sales cycles for our Enabling Technologies products, which may cause fluctuations in our financial results.
  • Our IONM business exposes us to risks inherent with the sale of services.
  • Our medical device products and operations are subject to extensive governmental regulation both in the U.S. and abroad, and our failure to comply with applicable requirements could cause our business to suffer.
  • Modifications to our products may require new 510(k) or de novo clearances, HDEs, PMAs or PMA supplements, or may require us to cease marketing or recall the modified products until clearances or approvals are obtained.
  • Our HCT/P products are subject to extensive government regulation, and our failure to comply with these requirements could cause our business to suffer.
  • If we or our suppliers fail to comply with the FDA’s good manufacturing practice regulations and similar international regulations, this could impair our ability to market our products in a cost-effective and timely manner.
  • A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us.
  • We may be subject to enforcement action if we engage in the off-label promotion of our products.
  • Governmental regulation and limited sources and suppliers could restrict our procurement and use of tissue.
  • Negative publicity concerning methods of tissue recovery and screening of donor tissue in our industry could reduce demand for our regenerative biologics products and impact the supply of available donor tissue.
  • We are subject to environmental laws and regulations that can impose significant costs and expose us to potential financial liabilities.
  • We or our suppliers may be the subject of claims for non-compliance with FDA regulations in connection with the processing, manufacturing or distribution of our proposed allograft or other regenerative biologics implants and products.
  • We and our distributor sales representatives might be subject to claims for failing to comply with U.S. federal, state, local and foreign fraud and abuse laws, including anti-kickback laws and other anti-referral laws.
  • We may fail to obtain or maintain foreign regulatory approvals to market our products in other countries.
  • We are subject to risks associated with our non-U.S. operations.
  • Our results of operations could suffer if we are unable to manage our planned international expansion effectively.
  • We are subject to risks arising from currency exchange rate fluctuations on our international transactions and translation of local currency results into U.S. dollars, which could adversely affect our profitability.
  • Tariff policies and potential countermeasures have and may continue to increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations.
  • We will need to generate significant sales to remain profitable.
  • We may be unable to grow our revenue or earnings as anticipated, which may have a material adverse effect on our results of operations.
  • Our quarterly and annual operating results may fluctuate significantly.
  • The availability of funding under existing credit arrangements may be limited, and our cash and cash equivalents are subject to volatility.
  • Our future capital needs are uncertain, and we may need to raise funds in the future, and such funds may not be available on acceptable terms or at all.
  • Our existing revolving credit facility contains restrictive covenants that may limit our operating flexibility.
  • Our ability to protect our intellectual property and proprietary technology is uncertain.
  • Patent litigation is highly prevalent in the medical device industry, and we could become subject to litigation that could be costly, result in the diversion of management’s time and efforts, require us to pay damages, and/or prevent us from marketing our existing or future products.
  • We may be subject to damages resulting from claims that we, our employees or our independent distributors have wrongfully used or disclosed alleged trade secrets, proprietary or confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
  • We may incur product liability losses and insurance coverage may be inadequate or unavailable to cover these losses.
  • Because of their significant stock ownership, our Executive Chairman, our other executive officers, and our directors and principal stockholders will be able to exert control over us and our significant corporate decisions.
  • We are a “controlled company” within the meaning of the New York Stock Exchange Rules, and we take, and intend to continue to take, advantage of exemptions from certain corporate governance requirements.
  • Our Board is authorized to issue and designate shares of our preferred stock in additional series without stockholder approval.
  • Anti-takeover provisions in our organizational documents and Delaware law may discourage or prevent a change of control, even if an acquisition would be beneficial to our stockholders, which could depress the price of our Class A common stock and prevent attempts by our stockholders to replace or remove our current management.
  • The Company’s Bylaws provide, to the fullest extent permitted by law, that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal actions between the Company and its stockholders, which could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Company’s directors, officers or other employees.
  • If we do not successfully implement our business strategy, our business and results of operations will be adversely affected.
  • Fluctuations in insurance cost and availability could adversely affect our profitability or our risk management profile.
  • We are exposed to the credit risk of some of our customers, which could result in material losses.
  • The widespread outbreak of a communicable disease, or any other public health crisis, could adversely affect our financial condition and results of operations.
  • We have and may continue seek to grow our business through acquisitions of or investments in new or complementary businesses, products or technologies, and the failure to manage acquisitions or investments, or the failure to integrate them with our existing business, could have a material adverse effect on us.
  • Integrating acquired businesses into Globus may be more difficult, costly or time-consuming than expected and the Company may fail to realize the anticipated benefits of such acquisitions, which may adversely affect the Company’s business results and negatively affect the value of the Company’s Class A common stock.

Legal proceedings

We are involved in a number of proceedings, legal actions and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within our control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions prohibiting us from engaging in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. For further details on the material legal proceedings to which we are currently a party, please refer to “Part II; Item 8. Financial Statements and Supplementary Data; Notes to Consolidated Financial Statements; Note 15. Commitments and Contingencies” below.

In addition, we are subject to legal proceedings arising in the ordinary course of business. Consistent with Item 103 of Regulation S-K, we have elected to disclose those environmental proceedings with a governmental entity as a party where the Company reasonably believes that such proceeding would result in monetary sanctions, exclusive of interest and costs, of $1.0 million or more. Applying this threshold, there are no environmental matters to disclose for the fiscal year ended December 31, 2025.

The opening of Item 3, Legal Proceedings.19

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Company websiteGlobus Medical logo
  6. 6
  7. 7
  8. 8
  9. 9
    Company websiteGlobus Medical photo
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
    SEC EDGAROther events
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67